MBX BIOSCIENCES INC.

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

28 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 سبتمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire